Delivery Order SPE2DB20D9135-SPE2DB25FZW79
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,107.10 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This delivery order represents a firm fixed-price contract with an ultimate completion date of September 30, 2025, and will be fulfilled from the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an...
- The Defense Logistics Agency awarded a $25.1K delivery order to DMS Pharmaceutical Group Inc. on July 21, 2025, for the supply of EXPAREL 266 mg/20 mL vials. EXPAREL is a liposomal bupivacaine product used for infiltration and nerve block anesthesia in surgical settings. This delivery order is issued without a set-aside designation and carries an ultimate completion date of August 11, 2025, under a firm fixed-price arrangement. The work will be performed in Park Ridge, Illinois, where DMS...
- This delivery order, awarded July 31, 2025, by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., covers the supply of EXPAREL 266 mg/20 mL vials. The contract is valued at $5,021.26 with an ultimate completion date of August 21, 2025, and operates under a firm fixed-price arrangement with no set-aside designation. EXPAREL is a liposomal bupivacaine product used for infiltration and nerve block anesthesia in surgical settings, reflecting the DLA's ongoing need to maintain...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. The contract, valued at $2,510.63 with a firm fixed-price structure, was executed on August 13, 2025, with an ultimate completion date of September 4, 2025. EXPAREL is a liposomal bupivacaine formulation used for extended local anesthesia, and this delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $10,042.52 to DMS Pharmaceutical Group Inc. on September 11, 2025, for the supply of EXPAREL 266 mg/20 mL vials. EXPAREL is a liposomal bupivacaine formulation used for surgical site infiltration and nerve block anesthesia. This firm fixed-price delivery order, with an ultimate completion date of October 2, 2025, will be delivered to Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,659.45 to DMS Pharmaceutical Group Inc. for EXPAREL 266 mg/20 mL vials. The order was issued on September 11, 2025, with an ultimate completion date of October 2, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The Defense Logistics Agency awarded a delivery order valued at $2,510.63 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. EXPAREL is a liposomal bupivacaine formulation used for local anesthesia and post-operative pain management in surgical settings. The contract utilizes firm fixed-price pricing and carries an ultimate completion date of August 21, 2025. This delivery order...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,574.41 to DMS Pharmaceutical Group Inc. on August 11, 2025, for the supply of EXPAREL 266 mg/20 mL vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its Park Ridge facility with an ultimate completion date of September 2, 2025. This delivery order was issued without a set-aside designation, allowing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 11, 2025, by the Defense Logistics Agency (DLA) for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, valued at $7,531.89 with an ultimate completion date of September 2, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- This delivery order, awarded on July 23, 2025, by the Defense Logistics Agency's Medical Supply Chain to DMS Pharmaceutical Group Inc., covers the supply of EXPAREL 266 mg/20 mL vials with a firm fixed price ceiling of $25,106.30 and an ultimate completion date of August 13, 2025. EXPAREL is a liposomal bupivacaine formulation used for surgical anesthesia and post-operative pain management. The award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- SPE2DB20D9135Indefinite Delivery Contract
- SPE2DB20D9135-SPE2DB25FZW79Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,510.63 to DMS Pharmaceutical Group Inc. on April 23, 2025, for the supply of EXPAREL 266 mg/20 mL vials. EXPAREL is a liposomal bupivacaine formulation used for local anesthetic infiltration during surgical procedures. This delivery order, with an ultimate completion date of May 14, 2025, represents a firm fixed-price procurement with no set-aside designation. The awardee, DMS Pharmaceutical Group Inc., is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, which serves as the place of performance for this contract. This delivery order was issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and extending through November 2026. This comprehensive IDC framework enables the DLA to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its consistent performance delivering branded and generic prescription drugs, biologics, and medical consumables to military health systems. The company's woman-owned small business status has enabled it to compete effectively in federal procurement markets while maintaining a robust portfolio of contract awards with the DLA since its SAM.gov registration in 2001.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 4/23/25 |